PDCD1 and acute myeloid leukemia: According to the authors, this observation suggests that PD-1 and PD-L1 inhibition might not be the same in AML and might help explain, at least in part, the apparent discrepancy in response rates and survival with PD-1 inhibitor- versus PD-L1 inhibitor-based therapies seen in the clinical trials in patients with AML.